After finishing at $4.81 in the prior trading day, Mersana Therapeutics Inc (NASDAQ: MRSN) closed at $4.70, down -2.29%. In other words, the price has decreased by -$0.1100 from its previous closing price. On the day, 1160789 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of MRSN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.36. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.77.
On February 29, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral and also upped its target price recommendation from $2 to $7.
Guggenheim Upgraded its Neutral to Buy on February 29, 2024, while the target price for the stock was maintained at $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 16 ’24 when Protopapas Anna sold 29,399 shares for $2.71 per share. The transaction valued at 79,671 led to the insider holds 125,153 shares of the business.
Lowinger Timothy B sold 10,409 shares of MRSN for $28,208 on Jan 16 ’24. The SVP, Chief Sci.&Tech. Officer now owns 199,329 shares after completing the transaction at $2.71 per share. On Jan 16 ’24, another insider, DeSchuytner Brian, who serves as the SVP, COO & CFO of the company, sold 9,327 shares for $2.71 each. As a result, the insider received 25,276 and left with 54,511 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRSN now has a Market Capitalization of 570.12M and an Enterprise Value of 394.67M. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.47 while its Price-to-Book (P/B) ratio in mrq is 15.37. Its current Enterprise Value per Revenue stands at 10.71 whereas that against EBITDA is -2.38.
Stock Price History:
Over the past 52 weeks, MRSN has reached a high of $9.62, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 4.1365, while the 200-Day Moving Average is calculated to be 2.6836.
Shares Statistics:
The stock has traded on average 2.30M shares per day over the past 3-months and 2.93M shares per day over the last 10 days, according to various share statistics. A total of 120.71M shares are outstanding, with a floating share count of 91.80M. Insiders hold about 24.32% of the company’s shares, while institutions hold 71.11% stake in the company. Shares short for MRSN as of Feb 29, 2024 were 7.14M with a Short Ratio of 3.10, compared to 6.65M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.89% and a Short% of Float of 6.41%.
Earnings Estimates
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of -$0.18 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.21, while EPS last year was -$0.52. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.13 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.25 and -$0.87 for the fiscal current year, implying an average EPS of -$0.66. EPS for the following year is -$0.72, with 7 analysts recommending between -$0.33 and -$0.91.
